Inflammation, Thrombogenesis, Fibrinolysis, and Vein Wall Remodeling After Deep Venous Thrombosis

  • Jose Antonio DiazEmail author
  • Daniel Durant MyersJr.


Venous thromboembolism and its sequelae, postthrombotic syndrome and chronic thromboembolic pulmonary hypertension, affect millions of people worldwide. The purpose of this chapter is to present recent and current research focused on defining the mechanism that drives vein wall remodeling aftervenous thrombosis.


Deep Vein Thrombosis Inferior Vena Cava Venous Thrombosis Tissue Factor Pathway Inhibitor Vein Wall 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The author’s would like to thank Dr. Katherine Shuster for her careful edits of this book chapter. Financial support was obtained from the Jobst Foundation Grant (to JAD and DDM).

Conflicts of InterestThe authors have no conflicts of interest to disclose.


  1. 1.
    Kitchens CS, Alving BM, Kessler CM. Consultative hemostasis and thrombosis. Philadelphia: W.B. Saunders Co.; 2002.Google Scholar
  2. 2.
    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton 3rd LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis. 2006;21(1):23–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Heit JA, Cohen AT, Anderson Jr FA, on Behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal Venous Thromboembolism (VTE) Events in the US (abstract). Blood. 2005;106(11):910.Google Scholar
  5. 5.
    Virchow R. Gesammelte Abhandlungen zur Wissenschaftlichen Medicin, vol. 520–525. Frankfurt: A M Von Meidinger Sohn; 1856.Google Scholar
  6. 6.
    Stewart GJ, Ritchie WG, Lynch PR. Venous endothelial damage produced by massive sticking and emigration of leukocytes. Am J Pathol. 1974;74(3):507–32.PubMedGoogle Scholar
  7. 7.
    Sacher RA. Thrombophilia: a genetic predisposition to thrombosis. Trans Am Clin Climatol Assoc. 1999;110:51–60; discussion 61.PubMedGoogle Scholar
  8. 8.
    Schulman S, Lindmarker P, Holmstrom M, Larfars G, Carlsson A, Nicol P, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4(4):734–42.PubMedCrossRefGoogle Scholar
  9. 9.
    McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006;368(9533):371–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol. 2008;28(3):387–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Stanley JC, Veith FJ, Wakefield TW (editors) Current Therapy in Vascular and Endovascular Surgery, 5th edition. Elsevier (in press).Google Scholar
  13. 13.
    Deroo S, Deatrick KB, Henke PK. The vessel wall: a forgotten player in post thrombotic syndrome. Thromb Haemost. 2010;104(4):681–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Myers Jr D, Farris D, Hawley A, Wrobleski S, Chapman A, Stoolman L, et al. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J Surg Res. 2002;108(2):212–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Wagner DD, Frenette PS. The vessel wall and its interactions. Blood. 2008;111(11):5271–81.PubMedCrossRefGoogle Scholar
  16. 16.
    Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA. 2000;97(25):13835–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Ahn ER, Lander G, Jy W, Bidot CJ, Jimenez JJ, Horstman LL, et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res. 2004;114(2):143–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwege V, et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol. 1994;153(7):3245–55.PubMedGoogle Scholar
  19. 19.
    Myers DD, Wakefield TW. Inflammation-dependent thrombosis. Front Biosci. 2005;10:2750–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Pluskota E, Woody NM, Szpak D, Ballantyne CM, Soloviev DA, Simon DI, et al. Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. Blood. 2008;112(6):2327–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Andrews RK, Berndt MC. Microparticles facilitate neutrophil/platelet crosstalk. Blood. 2008;112(6):2174–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Osanai T, Akutsu N, Fujita N, Nakano T, Takahashi K, Guan W, et al. Cross talk between prostacyclin and nitric oxide under shear in smooth muscle cell: role in monocyte adhesion. Am J Physiol Heart Circ Physiol. 2001;281(1):H177–82.PubMedGoogle Scholar
  23. 23.
    Wojcik BM, Wrobleski SK, Hawley AE, Wakefield TW, Myers Jr DD, Diaz JA. Interleukin-6: a potential target for post-thrombotic syndrome. Ann Vasc Surg. 2011;25(2):229–39.PubMedCrossRefGoogle Scholar
  24. 24.
    Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176(2):231–41.PubMedCrossRefGoogle Scholar
  26. 26.
    Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol. 2009;30(11):513–21.PubMedCrossRefGoogle Scholar
  27. 27.
    Wartha F, Henriques-Normark B. ETosis: a novel cell death pathway. Sci Signal. 2008;1(21):e25.CrossRefGoogle Scholar
  28. 28.
    Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13(4):463–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers Jr DD, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 2010;107(36):15880–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Meier TR, Myers Jr DD, Wrobleski SK, Zajkowski PJ, Hawley AE, Bedard PW, et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. Thromb Haemost. 2008;99(2):343–51.PubMedGoogle Scholar
  32. 32.
    Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood. 1985;65(1):32–40.PubMedGoogle Scholar
  33. 33.
    Crowther MA, Roberts J, Roberts R, Johnston M, Stevens P, Skingley P, et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost. 2001;85(3):390–4.PubMedGoogle Scholar
  34. 34.
    Akar N, Yilmaz E, Akar E, Avcu F, Yalcin A, Cin S. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A. Thromb Res. 2000;97(4):227–30.PubMedCrossRefGoogle Scholar
  35. 35.
    Zoller B, Garcia de Frutos P, Dahlback B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemost. 1998;79(4):802–7.PubMedGoogle Scholar
  36. 36.
    Gresele P. Platelets in thrombotic and non-thrombotic disorders: pathophysiology, pharmacology, and therapeutics. Cambridge/New York: Cambridge University Press; 2002.CrossRefGoogle Scholar
  37. 37.
    Diaz JA, Ballard-Lipka NE, Farris DM, Hawley AE, Wrobleski SK, Myers DD, et al. Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. J Vasc Surg. 2012;55:815–22.PubMedCrossRefGoogle Scholar
  38. 38.
    Varma MR, Moaveni DM, Dewyer NA, Varga AJ, Deatrick KB, Kunkel SL, et al. Deep vein thrombosis resolution is not accelerated with increased neovascularization. J Vasc Surg. 2004;40(3):536–42.PubMedCrossRefGoogle Scholar
  39. 39.
    Henke PK, Pearce CG, Moaveni DM, Moore AJ, Lynch EM, Longo C, et al. Targeted deletion of CCR2 impairs deep vein thrombosis resolution in a mouse model. J Immunol. 2006;177(5):3388–97.PubMedGoogle Scholar
  40. 40.
    Deatrick KB, Eliason JL, Lynch EM, Moore AJ, Dewyer NA, Varma MR, et al. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. J Vasc Surg. 2005;42(1):140–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Myers Jr DD, Henke PK, Bedard PW, Wrobleski SK, Kaila N, Shaw G, et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg. 2006;44(3):625–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Patterson KA, Zhang X, Wrobleski SK, Hawley AE, Lawrence DA, Wakefield TW, et al. Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res. 2012 Dec 28 (in press).PubMedCrossRefGoogle Scholar
  43. 43.
    Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851–1861.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Section of Vascular Surgery, Department of Surgery, School of MedicineUniversity of MichiganAnn ArborUSA

Personalised recommendations